Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by SABBOBCATon Nov 14, 2019 12:52pm

92 Views

Post# 30351551

RE:RE:RE:RE:RE:RE:RE:RE:RE:Egrifta SV Packaging

Philippe replied to me from his Gmail and said it was due to "FDA related issues".

SABBOBCAT wrote: I emailed Philippe this morning to ask him about the delay given the info I found. I will let you know when I hear back, if at all.

SPCEO1 wrote: My understanding of the latest on the introduction of SV is they expect it to be launched by the end of November and it will take about 6 months for all of the patients to be converted to it because the payors will approve the new versions at different points over that time frame.

SABBOBCAT wrote: Thanks JFM

jfm1330 wrote: At first management said it would be at the end of September, and now according to an afficial document found on Sedar, they say that F4 (SV) will gradually replace F1 before the end of Q4, so before the end of November.